VACCINES - PowerPoint PPT Presentation

1 / 24
About This Presentation
Title:

VACCINES

Description:

THERAPEUTIC VACCINE TRIALS. JONAS SALK IDEA - WHOLE, KILLED HIV TO HIV-POSITIVE ... THERAPEUTIC TRIALS. REMUNE - IMMUNE RESPONSE CORPORATION, CARLSBAD ... – PowerPoint PPT presentation

Number of Views:97
Avg rating:3.0/5.0
Slides: 25
Provided by: sandi84
Category:
Tags: vaccines | trials

less

Transcript and Presenter's Notes

Title: VACCINES


1
VACCINES
2
PROPHYLACTIC
  • TO HIV NEGATIVE
  • TO PREVENT INFECTION

3
THERAPEUTIC
  • TO HIV-POSITIVE
  • TO BOOST IMMUNE SYSTEM TO FIGHT HIV

4
KILLED VACCINE
  • WHOLE VIRUS, KILLED - COAT, CORE,...
  • DISRUPTED BY HEATING OR CHEMICAL TREATMENT TO
    KILL THE VIRUS
  • E.G., SALK POLIO VACCINE

5
(No Transcript)
6
LIVE VACCINE
  • ATTENUATED WEAKENED
  • VIRUS IS ABLE TO INFECT AND REPRODUCE AND
    STIMULATE IMMUNE SYSTEM, BUT UNABLE TO CAUSE
    DISEASE
  • E.G., SABIN POLIO VACCINE

7
VACCINE TRIALS - HIV/U.S.
  • FEAR OF WHOLE VIRUS, KILLED OR ATTENUATED
  • RATHER, USE PARTS OF HIV
  • COAT PROTEIN GP120 OR GP160
  • INTERNAL PROTEIN P24
  • ALONE OR IN COMBINATION

8
(No Transcript)
9
TRIAL STAGES
  • PHASE I - SAFETY
  • PHASE II - IMMUNE RESPONSE
  • B CELLS gt ANTIBODY
  • T8 CELLS gt T-KILLER ACTIVITY
  • PHASE III - EFFICACY - PREVENT INFECTION?

10
VACCINE TRIALS - U.S.COAT PROTEIN - GP120/160
  • PHASE I - SAFE - YES
  • PHASE II - IMMUNE RESPONSE - YES
  • BOTH ARMS - B AND T
  • PHASE III - EFFICACY?
  • PREVENT INFECTION?

11
PHASE III - EFFICACY - SURROGATE TEST
  • INJECT LIVE, PATHOGENIC HIV TO VACCINEES?
    UNETHICAL
  • SURROGATE TEST - DO ANTIBODIES OF VACCINEES BLOCK
    HIV INFECTION OF HUMAN CELLS?
  • LAB STRAIN OF HIV - YES
  • PRIMARY ISOLATES OF HIV - NO

12
(No Transcript)
13
PHASE III - EFFICACY
  • PREVENT INFECTION?

14
(No Transcript)
15
DON FRANCIS, CDC TO GENENTECH TO VaxGen
  • FDA - PHASE III APPROVAL
  • REFORMULATED COAT
  • U.S. 5,000 -STRAIN B - HIGH RISK GAY/HETEROS
  • THAILAND 2,500 - STRAINS B E
  • HIV-NEGATIVE, HIV ANTIBODY
  • COMPLETION IN 2003

16
(No Transcript)
17
THERAPEUTIC VACCINE TRIALS
  • JONAS SALK IDEA - WHOLE, KILLED HIV TO
    HIV-POSITIVE
  • BOOST IMMUNE RESPONSE, LOWER VIRAL LOAD OR
    ELIMINATE VIRUS

18
THERAPEUTIC TRIALS
  • REMUNE - IMMUNE RESPONSE CORPORATION, CARLSBAD
  • FIRST 300 - EFFICACY NOT YET DEMONSTRATED
  • FDA APPROVAL TO ENROLL MORE

19
IMMUNE TRIALS - FUTURE
  • DEVELOPING WORLD - 6 MILLION NEW INFECTIONS PER
    YEAR
  • STRAIN SPECIFIC FOR EACH COUNTRY?
  • COCKTAIL?

20
VACCINE STUDIES?
  • RATIONALIST- NEED EVIDENCE OF EFFICACY!
  • EMPIRICIST - LEARN AS WE GO
  • ETHICS OF DOING NOTHING?
  • DON FRANCIS - THEORETICAL BABBLING OF CRITICS

21
HIV - LIVE, ATTENUATED
  • CHARLES FARTHING, AIDS HEALTHCARE FOUNDATION, LA
  • IAPAC - INTERNATIONAL ASSOCIATION OF PHYSICIANS
    IN AIDS CARE - 5,500 MEMBERS
  • RECRUIT A FEW HUNDREDS FOR TRIAL IN 2000

22
LIVE, ATTENUATED
  • MUTATE TO PATHOGENIC?
  • SIV-D3 - SIV VACCINE
  • ATTENUATED FOR ADULTS
  • INFECTS AND KILLS NEONATES
  • 10 YEARS, ADULTS TO S-AIDS
  • ENTRY INTO DNA - RISK OF CANCER

23
RETROVIRUS VACCINE?
  • VACCINES DO NOT PREVENT INFECTION - THEY QUICKEN
    AND ENHANCE IMMUNE RESPONSE WHICH STOPS
    PROGRESSION OF INFECTION TO DISEASE
  • RETROVIRUS INFECTION - VACCINE TOO LATE? HIV
    SEEDED THRU BODY

24
PERVERSE OUTCOME
  • VACCINE MAY BE LESS THAN 100 EFFECTIVE IN
    BLOCKING INFECTION
  • VACCINEE FEELING PROTECTED, MIGHT CONTINUE RISK
    ACTIVITIES
Write a Comment
User Comments (0)
About PowerShow.com